Ipsen
Ipsen S.A., a global biopharmaceutical group headquartered in France, has established itself as a leader in the healthcare industry since its founding in 1929. With a strong presence in Europe, North America, and Asia, Ipsen focuses on innovative treatments in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Cabometyx®, which are distinguished by their unique mechanisms of action and efficacy in treating complex conditions. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. Recognised for its dedication to patient care and innovation, Ipsen continues to make strides in the biopharmaceutical sector, contributing to advancements that improve the quality of life for patients worldwide.
DitchCarbon Score
How does Ipsen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen's score of 80 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipsen's reported carbon emissions
In 2024, Ipsen reported total Scope 1 emissions of approximately 9,932,000 kg CO2e globally, with significant contributions from various regions, including 2,659,700 kg CO2e from France and 2,657,000 kg CO2e from the Czech Republic. The company also disclosed Scope 2 emissions of about 289,000 kg CO2e globally, alongside substantial Scope 3 emissions, which totalled approximately 90,705,000 kg CO2e. Ipsen has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2019 as the baseline year. Additionally, the company targets a 20% reduction in Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and contribute to the global goal of limiting warming to 1.5°C. Furthermore, Ipsen has a long-term objective to achieve net-zero emissions by 2045, aiming for at least a 90% reduction in all scopes of emissions from the 2019 baseline, balancing any remaining emissions with high-quality carbon removal strategies. Ipsen's commitment to sustainability reflects its proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,024,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 15,399,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipsen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
